ReviewMovement disorders : official journal of the Movement Disorder Society2016
Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.
Review in Movement disorders : official journal of the Movement Disorder Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Available and future treatments for atypical parkinsonism. A systematic review.CNS neuroscience & therapeutics · 2019Pooled it
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.Nature medicine · 2021Trial
- Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.Movement disorders : official journal of the Movement Disorder Society · 2017Trial
- Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.Movement disorders : official journal of the Movement Disorder Society · 2016Trial
- PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.Journal of neurology · 2016Trial
- Longitudinal Cognitive Function in Progressive Supranuclear Palsy-A Review of the Evidence for Progression.Movement disorders clinical practice · 2026Review
- Glycogen Synthase Kinase-3β Inhibition Ameliorates Synaptic and Mitochondrial Dysfunction in a Sporadic Alzheimer's Disease-Like Model.Molecular neurobiology · 2026Article
- Cognitive impairment on the Alzheimer's Disease Centers' Uniform Data Set Version 3 Neuropsychological Test Battery in a Peruvian population with progressive supranuclear palsy.Arquivos de neuro-psiquiatria · 2026Article
- Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Cross-sectional and longitudinal validation of short and long versions of the progressive supranuclear palsy quality of life scale.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance.Nature communications · 2025Article
- Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials.Brain communications · 2025Review
- Combined Assessment of Function and Survival to Demonstrate the Effect of Treatment on Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials.Brain : a journal of neurology · 2023Article
- Efficacy of faecal microbiota transplantation in patients with progressive supranuclear palsy-Richardson's syndrome: a phase 2, single centre, randomised clinical trial.EClinicalMedicine · 2023Article
- Longitudinal clinical decline and baseline predictors in progressive supranuclear palsy.Parkinsonism & related disorders · 2023Article
- Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway.Stem cell research & therapy · 2022Article
- A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study.BMJ neurology open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 4 countries.
Funding
Abstract
backgroundTwo recent randomized, placebo-controlled trials of putative disease-modifying agents (davunetide, tideglusib) in progressive supranuclear palsy (PSP) failed to show efficacy, but generated data relevant for future trials.
methodsWe provide sample size calculations based on data collected in 187 PSP patients assigned to placebo in these trials. A placebo effect was calculated.
resultsThe total PSP-Rating Scale required the least number of patients per group (N = 51) to detect a 50% change in the 1-year progression and 39 when including patients with ≤ 5 years disease duration. The Schwab and England Activities of Daily Living required 70 patients per group and was highly correlated with the PSP-Rating Scale. A placebo effect was not detected in these scales.
conclusionsWe propose the 1-year PSP-Rating Scale score change as the single primary readout in clinical neuroprotective or disease-modifying trials. The Schwab and England Activities of Daily Living could be used as a secondary outcome. © 2016 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.